Children’s National Health System touted data today from a Phase I dose-ranging study evaluating a cell therapy approach in patients with blood and bone marrow cancers for whom stem cell transplantation hasn’t worked.
Results from the Resolve trial showed that 78% of patients responded to multi-tumor-associated antigen specific lymphocytes (TAA-L) treatment and 44% of patients had complete remission with limited toxicity, according to Children’s National.
Get the full story at our sister site, Drug Delivery Business News.